• SIGN IN
  • GET HELP
  •  

    Webinar Details


    Event Type

    Live Online

    Date

    Thursday, March 28, 2019

    Time

    8:00 PM - 10:00 PM ET

    Location

    PharmCon Webinar Studio (freeCE.com)

    Credits

    2 Contact Hour(s)

    Target Audience

    Pharmacist, Nurse

    Cost

    $0.00

    • Overview

      Patients with diabetes are much more likely to suffer from cardiovascular disease than those without diabetes. In fact, cardiovascular disease is the leading cause of death associated with diabetes. Findings from several recent clinical trials highlight the limitations of focusing exclusively on glycemic treatment goals for type 2 diabetes (T2D) and emphasize the need for cardiovascular risk reduction as well. Pharmacists are often the medical professional that patients reach out to for guidance and explanation on new pharmacotherapy and individualized treatment. This educational opportunity will give participants an in depth look at the clinical evidence behind the changes and opportunities for individualized treatment of T2D and in particular those with higher CVD risk to improve patient outcomes.


      Handouts

      Slide Document 19009L01_6pp(001).pdf
      Slide Document 19009L01_2pp(001).pdf





      Financial Support By

      Novo Nordisk
    • Pharmacist

      Review the current treatment guidelines for T2D in patients at risk for cardiovascular events
      Outline the results of cardiovascular outcomes trials of antihyperglycemic therapies in patients with T2D.
      Compare and contrast evidence-based treatment options that optimize glycemic control and reduce cardiovascular events in patients with type 2 diabetes.
      Identify approaches to communicate the potential cardiovascular benefits and risk of various treatment approaches for diabetes to patients and members of the healthcare team.

      Nurse

      Review the current treatment guidelines for T2D in patients at risk for cardiovascular events
      Outline the results of cardiovascular outcomes trials of antihyperglycemic therapies in patients with T2D.
      Compare and contrast evidence-based treatment options that optimize glycemic control and reduce cardiovascular events in patients with type 2 diabetes.
      Identify approaches to communicate the potential cardiovascular benefits and risk of various treatment approaches for diabetes to patients and members of the healthcare team.
    • Repeat Presentation

      This presentation was last given on 4/15/2019 2:00 PM

      Future Airings

      Date Time
      Monday, April 15, 2019 2:00 PM View

    • Activity Type

      Knowledge

      CE Broker

      20-646643

      Universal Activity Number

      Pharmacist 0798-0000-19-009-L01-P

      Nurse 0798-0000-19-009-L01-N

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, attendees must answer poll questions and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.


    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).




    Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.